Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q4 FY2020 Earnings Presentation
17 slides from Cencora's earnings presentation, Nov 5, 2020
Slide 1: Q4 & Full Year FY2020 Financial Results
Q4 & Full Year FY2020 Financial Results November 5, 2020
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "ou
Slide 3: AmerisourceBergen is united in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen drives innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain. 3
Slide 4: Financial Results: Overview
Financial Results: Overview • Solid year-over-year revenue and adjusted diluted EPS growth Delivered Strong Fiscal • Continued leadership in Specialty Distribution and Services 2020 Performance • Revenue and operating income growth in both Pharmaceutical Distribution Services and Other • Delivering
Slide 5: Q4 FY2020 Financial Results
Q4 FY2020 Financial Results Adjusted GAAP (non-GAAP)1 Revenue $49.2B $49.2B % Change (Year-over-Year) 7.9% 7.9% Gross Profit $1.3B $1.3B % Change 13.7% 6.4% Operating Expenses $7,460M $795M % Change 642.4% 0.8% Operating (Loss) Income $(6,113)M $530M % Change (3,499.2)% 16.2% Interest Expense, Net $
Slide 6: Full Year FY2020 Financial Results
Full Year FY2020 Financial Results Adjusted GAAP (non-GAAP)1 Revenue $189.9B $189.9B % Change (Year-over-Year) 5.7% 5.7% Gross Profit $5.2B $5.2B % Change 1.0% 4.4% Operating Expenses $10.3B $3.0B % Change 156.5% 2.3% Operating (Loss) Income $(5.1)B $2.2B % Change (561.8)% 7.5% Interest Expense, Net
Slide 7: Q4 FY2020 Financial Results: Pharmaceutical Distribution Services Segment
Q4 FY2020 Financial Results: Pharmaceutical Distribution Services Segment Q4 FY2020 Q4 FY2019 Revenue $47.3B $43.9B Operating Income $425.6M $369.3M Percentages of Revenue Gross Profit 2.05% 2.07% Operating Expenses 1.15% 1.23% Operating Income 0.90% 0.84% ▪ Revenue increased primarily due to contin
Slide 8: Other – Global Commercialization Services & Animal Health
Q4 FY2020 Financial Results: Other – Global Commercialization Services & Animal Health Q4 FY2020 Q4 FY2019 Revenue $2.0B $1.8B Operating Income $104.5M $86.7M Percentages of Revenue Gross Profit 18.08% 18.76% Operating Expenses 12.83% 13.93% Operating Income 5.25% 4.83% ▪ Revenue growth at all three
Slide 9: Differentiated and positioned for growth
Differentiated and positioned for growth Customer Base Innovative Services & • Key anchor customers Solutions • Fast growing • Customer-focused offerings • U.S. Pharmaceutical focus serving manufacturers and provider customers Leadership in Specialty Successful Corporate Distribution & Services Stew
Slide 10: FY21 Financial Guidance
FY21 Financial Guidance Expectations on an Adjusted (non-GAAP) Basis Revenue Mid-single digit percent growth Diluted Earnings Per Share $8.20 to $8.45 Operating Expense Mid-single digit percent growth Operating Income Mid-single digit percent growth Pharmaceutical Distribution Services Mid-single di
Slide 11: Appendix
Appendix N) AmerisourceBergen’
Slide 12: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 13
Slide 14: GAAP to Non-GAAP Reconciliations
B Appendix AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (ia thousands, except per share data) (unaudited) Fiscal Year Ended September 30, 2020 ‘Net (Loss) (Loss) Income AMABSE, Tacome Diluted Operating Operating (Loss) Before Tucome _IncomeTax —Noncontroling Attributable to Earning
Slide 15: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 15
Slide 16: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 16
Slide 17: AmerisourceBergen
N) AmerisourceBergen’ Where knowledge, reach and partnership shape healthcare delivery.